Veterinary monoclonal antibodies for companion and production animal health
A development programme producing recombinant monoclonal antibodies and related biological therapeutics for veterinary applications, manufactured via a non-conventional yeast expression platform. Initial focus on companion animal indications, with a pathway to production animal applications.
Manufacturing costs and platform limitations have constrained the range of antibody-based therapeutics available in animal health. A lower-cost yeast-based route to recombinant veterinary mAbs enables both more affordable versions of existing product categories and access to therapeutic targets not currently viable to develop. Beyond economics, our platform produces proteins with distinct glycosylation profiles that may confer novel immunomodulatory properties — a potentially valuable and underexplored dimension of veterinary biologics.
Early development stage. Target selection and feasibility assessment ongoing for initial companion animal indications. Seeking co-development partners who bring validated therapeutic targets or disease model access.
Looking to connect with animal health companies, veterinary biologics developers, or academic groups with validated antibody targets who need a manufacturing partner.
About HERlab
HERlab is a synthetic biology company that develops advanced microbial platforms to overcome challenges in protein discovery and production. By utilizing machine learning and a vast library of unconventional host microorganisms, the company's platform matches specific proteins to their ideal expression machinery. This approach enables the discovery and optimization of production systems for proteins, small molecules, and glycans that are often difficult to develop using standard industrial models. The company focuses on streamlining the expression and validation phases of bioproduction to improve scalability and efficiency.
The company's work addresses significant bottlenecks in precision fermentation, where reliance on a limited number of standard yeast hosts often results in prohibitively high production costs. By unlocking the potential of non-conventional yeasts, HERlab aims to lower expenses related to feedstock, purification, and genetic engineering. These capabilities are intended to facilitate more accessible and sustainable production of biomolecules, including food ingredients, vitamins, and chemicals, supporting the transition away from resource-intensive animal-based production methods. HERlab was founded in 2022 and has participated in accelerator programs such as Katapult to advance its climate and industrial biotechnology solutions.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.